Update: Getting closer to data
Relmada is making progress with its emerging pain pipeline. The company reported positive results from a Phase I trial of d-Methadone and continues to add cohorts to the study. A pharmacokinetic study comparing its proprietary oral formulations of buprenorphine to marketed sublingual and intravenous versions has also started; these key data will be available in H215. We value Relmada at $596m or $11.10 per basic share.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.